PTMA抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P06699(HLA-A/F/H Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P06699(HLA-A/F/H Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of PTMA Antibodies**

Prothymosin alpha (PTMA) is a highly conserved, acidic nuclear protein involved in critical cellular processes, including cell proliferation, apoptosis, and chromatin remodeling. Initially identified as a thymic hormone precursor, PTMA is ubiquitously expressed across tissues and plays roles in regulating immune responses, oxidative stress, and oncogenesis. Its interaction with key proteins like p53 and MDM2 underscores its importance in tumor suppression and cancer progression.

PTMA antibodies are immunological tools developed to detect and quantify PTMA expression in research and clinical settings. These antibodies are essential for studying PTMA's dual role in cancer—acting as both a pro-survival factor in malignancies (e.g., hepatocellular carcinoma, leukemia) and a mediator of chemotherapy-induced apoptosis. Elevated PTMA levels are linked to poor prognosis in several cancers, making it a potential diagnostic or prognostic biomarker.

In autoimmune diseases, PTMA antibodies have been investigated due to PTMA's immunomodulatory properties and its presence in autoantigen complexes. Additionally, PTMA's nuclear localization signal (NLS) and nucleolar translocation during stress responses are areas of active research, facilitated by specific antibodies.

Challenges in PTMA antibody development include its high homology across species and structural variability due to post-translational modifications. Nonetheless, advances in monoclonal antibody technology have improved specificity, enabling precise detection in immunohistochemistry, Western blotting, and flow cytometry. Ongoing studies aim to harness PTMA-targeting antibodies for therapeutic strategies, particularly in oncology and immune regulation.